TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regre... TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. 詳細を表示
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear...
BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today...
The clinical trial Safety Review Committee (SRC) approved opening of Cohort 2 after review of safety data from the three patients comprising Cohort 1No significant safety or dose limiting...
Patients currently remain on study for continued treatment with TTX-MC138 No significant safety or dose limiting toxicities reportedTTX-MC138, an antisense oligonucleotide conjugated to...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0311 | -8.46719303022 | 0.3673 | 0.3823 | 0.3144 | 200299 | 0.33781093 | CS |
4 | -0.3198 | -48.75 | 0.656 | 0.6969 | 0.313 | 448922 | 0.4746579 | CS |
12 | 0.0583 | 20.9787693415 | 0.2779 | 0.8 | 0.2226 | 1724881 | 0.48120183 | CS |
26 | -0.8638 | -71.9833333333 | 1.2 | 1.99 | 0.216 | 1323387 | 0.52688167 | CS |
52 | -8.8638 | -96.3456521739 | 9.2 | 18.664 | 0.216 | 1482771 | 2.60123879 | CS |
156 | -2175.6638 | -99.9845496324 | 2176 | 2504 | 0.216 | 1493047 | 211.63349313 | CS |
260 | -4799.6638 | -99.9929958333 | 4800 | 5600 | 0.216 | 1679169 | 852.74521267 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約